{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:56Z","timestamp":1793394116385,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bulcan.2023.02.022","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T09:54:25Z","timestamp":1687946065000},"page":"1129-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Therapy-related myelodysplastic syndromes in the genomics era"],"prefix":"10.1016","volume":"110","author":[{"given":"Aline","family":"Renneville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Micol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.02.022_bib0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beha.2019.02.006","article-title":"Clonal hematopoiesis and therapy related MDS\/AML","volume":"32","author":"Desai","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0280","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification\u00a0\u2013\u00a0an approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0285","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0290","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0295","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0300","doi-asserted-by":"crossref","first-page":"374e4","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0305","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ajh.21828","article-title":"Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005\u20132006","volume":"85","author":"de Roos","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0310","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0315","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0320","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4006.4006","article-title":"Survival improvement in therapy related myeloid neosplasm? A single center analysis of 428 patients","volume":"128","author":"Saleh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0325","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11899-022-00676-2","article-title":"Role of germline predisposition to therapy-related myeloid neoplasms","volume":"17","author":"Baranwal","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0330","doi-asserted-by":"crossref","first-page":"e187147","DOI":"10.1001\/jamanetworkopen.2018.7147","article-title":"Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in france","volume":"2","author":"Jabagi","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0335","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","article-title":"Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience","volume":"33","author":"Wolff","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0340","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0345","doi-asserted-by":"crossref","first-page":"23284","DOI":"10.1038\/s41598-021-02497-4","article-title":"Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States","volume":"11","author":"Singh","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0350","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0355","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0360","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0365","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood.2021010764","article-title":"What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms","volume":"138","author":"Voso","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0370","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0375","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0380","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0385","first-page":"128","article-title":"From clonal hematopoiesis to therapy-related myeloid neoplasms: the silent way of cancer progression","volume":"10","author":"Gurnari","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0390","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(15)00094-0","article-title":"Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study","volume":"2","author":"Leuraud","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0395","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0400","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.blre.2016.11.002","article-title":"Therapy-related myelodysplastic syndromes, or are they?","volume":"31","author":"Abou Zahr","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0410","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tig.2021.08.007","article-title":"Therapeutic and prognostic insights from the analysis of cancer mutational signatures","volume":"38","author":"Brady","year":"2022","journal-title":"Trends Genet"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0415","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0420","doi-asserted-by":"crossref","first-page":"700e6","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0425","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2643-3230.BCD-19-0028","article-title":"Cytotoxic therapy\u00a0\u2013\u00a0induced effects on both hematopoietic and marrow stromal cells promotes therapy-related myeloid neoplasms","volume":"1","author":"Stoddart","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0430","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/s41375-022-01686-y","article-title":"A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure","volume":"36","author":"Kutyna","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0435","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0440","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0445","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0450","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0455","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0460","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0465","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/bloodadvances.2019000293","article-title":"Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years","volume":"3","author":"Borate","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0470","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.leukres.2013.02.014","article-title":"Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS\/AML): a report on 54 patients by the Groupe francophone des my\u00e9lodysplasies (GFM)","volume":"37","author":"Bally","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0475","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2017.01.024","article-title":"Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease","volume":"55","author":"Annereau","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0480","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0485","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0490","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0495","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0500","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0505","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2022-163841","article-title":"Prolonged survival in bi-allelic TP53-mutated (TP53 mut) MDS subjects treated with oral decitabine\/cedazuridine in the ascertain trial (ASTX727-02)","volume":"140","author":"Savona","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0510","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0515","doi-asserted-by":"crossref","first-page":"9821","DOI":"10.1182\/blood-2022-162278","article-title":"Molecular response analysis by high throughput sequencing in higher risk myelodysplastic syndrome (HR-MDS) treated intensively with CPX-351","volume":"140","author":"le Bris","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0520","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0525","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41409-022-01686-7","article-title":"Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the chronic malignancies working party of the EBMT","volume":"57","author":"Nabergoj","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0530","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/hon.2991","article-title":"Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a propensity score matched analysis","volume":"40","author":"Itonaga","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0535","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.022_bib0540","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0959-8049(22)00830-9","article-title":"Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer","volume":"174","author":"Tagliamento","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:43Z","timestamp":1757792323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0007455123002771"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.022","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-related myelodysplastic syndromes in the genomics era","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}